期刊
JOURNAL OF BIOSCIENCE AND BIOENGINEERING
卷 128, 期 4, 页码 487-494出版社
SOC BIOSCIENCE BIOENGINEERING JAPAN
DOI: 10.1016/j.jbiosc.2019.04.005
关键词
HEK293 cells; Dihydrofolate reductase; Methotrexate; Hypoxanthine-thymidine; Protein expression; Biotherapeutics
资金
- National Natural Science Foundation of China [31770853, 21778023]
- Young Thousand Program
- Program of Introducing Talents of Discipline to Universities [111-2-06]
- National first-class discipline program of Light Industry Technology and Engineering [LITE2018-015]
- Top-notch Academic Programs Project of Jiangsu Higher Education Institutions
- International Joint Research Laboratory for Investigation of Glycoprotein Biosynthesis at Jiangnan University
Since the use of protein therapeutics is effective for treating intractable human diseases, the production of biologic therapeutic agents has dramatically increased over the past three decades. The Chinese hamster ovary (CHO) cell lines are the most commonly used host cell expression system for recombinant protein production. High productive and stable clonal cell lines for recombinant protein production have been established from the DHFR-deficient CHO cell using the dihydrofolate reductase/methotrexate (DHFR/MTX) selection methods. Human embryonic kidney 293 (HEK293) cells are alternative host cells widely used for protein production. In most case, however, the cells are used for the transient expression, and there is no gene amplification system in HEK293 cells. In this study, we established a DHFR-deficient HEK293 cell line for the high yield of recombinant proteins. We doubly knocked out DHFR and DHFR2 in the MAN1A1/A2/B1/C1-quadruple knockout HEK293 (QD-KO) cells, using the CRISPR/Cas9 system. The DHFR-deficient QD-KO cells were used to overexpress two proteins, lysosomal acid lipase and the constant fragment of human immunoglobulin G(1) by the DHFR/MTX gene-amplification method. This method resulted in a dramatic increase in the two protein expressions in the DHFR-deficient QD-KO cells by increasing MTX concentration. Our system could be adopted in the production of several recombinant proteins including therapeutic proteins. (C) 2019, The Society for Biotechnology, Japan. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据